Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -52.40% is 20% above its 5-year average of -65.76%, near the high end of its 5-year range (-104.69%–-37.81%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.73% above its 12-month average of -61.45%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -52.40%.
RETURN ON INVESTED CAPITAL (ROIC)
-52.40%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-61.45%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-63.63%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-65.76%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.73%
CURRENT VS 3Y AVG
+17.66%
CURRENT VS 5Y AVG
+20.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.50%
median of 671 covered companies
CURRENT VS SECTOR MEDIAN
-56.42%
vs the sector median at left
Kalaris Therapeutics Inc
Market Cap
$63.26M
Return on Invested Capital (ROIC)
-52.40%
TTM Avg
-61.45%
3Y Avg
-63.63%
5Y Avg
-65.76%
Market Cap
$63.23M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-165.22%
3Y Avg
-160.52%
5Y Avg
-107.11%
Market Cap
$63.14M
Return on Invested Capital (ROIC)
-4.72%
TTM Avg
-4.96%
3Y Avg
-2.45%
5Y Avg
-3.32%
Market Cap
$63.78M
Return on Invested Capital (ROIC)
-56.22%
TTM Avg
-67.31%
3Y Avg
-52.91%
5Y Avg
-45.67%
Market Cap
$64.13M
Return on Invested Capital (ROIC)
-6.79%
TTM Avg
-4.87%
3Y Avg
-47.70%
5Y Avg
-62.00%
Market Cap
$61.21M
Return on Invested Capital (ROIC)
-79.68%
TTM Avg
-67.52%
3Y Avg
-59.81%
5Y Avg
-47.97%
Market Cap
$66.02M
Return on Invested Capital (ROIC)
-83.74%
TTM Avg
-153.15%
3Y Avg
-164.21%
5Y Avg
-165.99%
Market Cap
$60.49M
Return on Invested Capital (ROIC)
-3699.99%
TTM Avg
-104.88%
3Y Avg
-89.50%
5Y Avg
-74.29%
Market Cap
$60.32M
Return on Invested Capital (ROIC)
-136.77%
TTM Avg
-80.48%
3Y Avg
-75.99%
5Y Avg
-77.22%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $63.26M | -52.40% | -61.45% | -63.63% | -65.76% |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | -165.22% | -160.52% | -107.11% |
| InterCure Ltd. (INCR)vs › | $63.14M | -4.72% | -4.96% | -2.45% | -3.32% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | -56.22% | -67.31% | -52.91% | -45.67% |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.13M | -6.79% | -4.87% | -47.70% | -62.00% |
| Adicet Bio, Inc. (ACET)vs › | $61.21M | -79.68% | -67.52% | -59.81% | -47.97% |
| Cingulate Inc. (CING)vs › | $66.02M | -83.74% | -153.15% | -164.21% | -165.99% |
| PDS Biotechnology Corporation (PDSB)vs › | $60.49M | -3699.99% | -104.88% | -89.50% | -74.29% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.32M | -136.77% | -80.48% | -75.99% | -77.22% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.17M | -1235.48% | -801.38% | -433.95% | -312.84% |
ROIC
-52.4%
ROE
-76.8%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -52.40% |
| 2026-03-31 | -46.82% |
| 2025-12-31 | -41.08% |
| 2025-09-30 | -73.06% |
| 2025-06-30 | -93.89% |
| 2025-03-31 | -74.95% |
| 2024-12-31 | -56.59% |
| 2024-06-30 | -44.22% |
| 2024-03-31 | -72.27% |
| 2023-09-30 | -77.96% |
| 2023-06-30 | -66.73% |
| 2023-03-31 | -75.32% |
| 2022-12-31 | -65.87% |
| 2022-09-30 | -67.87% |
| 2022-06-30 | -104.69% |
| 2022-03-31 | -84.80% |
| 2021-12-31 | -66.51% |
| 2021-09-30 | -46.69% |
| 2021-06-30 | -37.81% |
| 2021-03-31 | -27.11% |
| 2020-12-31 | -19.71% |
| 2020-09-30 | -14.45% |
| 2020-06-30 | -35.67% |
| 2020-03-31 | -27.21% |
| 2019-12-31 | -20.02% |
